LVTX - LAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20 revenue of $6.99M beats by $3.49M May, 21 2024 07:37 AM LAVA Therapeutics N.V. 2024-05-21 07:37:51 ET More on LAVA Therapeutics Lava gets $7M from Pfizer as trial for cancer drug advances Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics For further details see: LAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20, revenue of $6.99M beats by $3.49M